[Editorial] Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on "Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients"
- Clin. Mol. Hepatol., Oct 2024, 30 (4) | https://doi.org/10.3350/cmh.2024.0346